Evidence map›Paper›PMID 26880111›Full record

ArticleScientific reports2016

Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model.

Nicanor Obaldía, Geoffrey S Dow, Lucia Gerena, Dennis Kyle, William Otero, Pierre-Yves Mantel, Nicholas Baro, Rachel Daniels, Angana Mukherjee, Lauren M Childs and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. The human malaria-Antimicrobial agents and chemotherapy · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Nicanor ObaldíaDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Geoffrey S DowWalter Reed Army Institute of Research, Silver Springs, MD, United States.
Lucia GerenaWalter Reed Army Institute of Research, Silver Springs, MD, United States.
Dennis KyleDepartment of Global Health, University of South Florida, Tampa, FL, United States.
William OteroCenter for the Evaluation of Antimalarial Drugs and Vaccines, Tropical Medicine Research/Instituto Conmemorativo Gorgas de Estudios de la Salud, Panamá City, Republic of Panama.
Pierre-Yves MantelDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Nicholas BaroDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Rachel DanielsDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Angana MukherjeeDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Lauren M ChildsCenter for Communicable Disease Dynamics and Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Caroline BuckeeCenter for Communicable Disease Dynamics and Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Manoj T DuraisinghDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Sarah K VolkmanDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Dyann F WirthDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Matthias MartiDepartment of Immunology and Infectious Diseases, Harvard | T.H. Chan School of Public Health, Boston, MA, United States.
Harvard University · USInstituto Conmemorativo Gorgas de Estudios de la Salud · PAWalter Reed Army Institute of Research · USCenter for Disease Dynamics, Economics & Policy · USUniversity of South Florida · US

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
NIGMS NIH HHS U54 GM088558NIGMS NIH HHS U54GM088558
6 · The paper itself

Abstract

Infections with Plasmodium falciparum, the most pathogenic of the Plasmodium species affecting man, have been reduced in part due to artemisinin-based combination therapies. However, artemisinin resistant parasites have recently emerged in South-East Asia. Novel intervention strategies are therefore urgently needed to maintain the current momentum for control and elimination of this disease. In the present study we characterize the phenotypic and genetic properties of the multi drug resistant (MDR) P. falciparum Thai C2A parasite strain in the non-human Aotus primate model, and across multiple passages. Aotus infections with C2A failed to clear upon oral artesunate and mefloquine treatment alone or in combination, and ex vivo drug assays demonstrated reduction in drug susceptibility profiles in later Aotus passages. Further analysis revealed mutations in the pfcrt and pfdhfr loci and increased parasite multiplication rate (PMR) across passages, despite elevated pfmdr1 copy number. Altogether our experiments suggest alterations in parasite population structure and increased fitness during Aotus adaptation. We also present data of early treatment failures with an oral artemisinin combination therapy in a pre-artemisinin resistant P. falciparum Thai isolate in this animal model.

Indexed as

Adaptation, BiologicalDrug ResistanceHost-Pathogen InteractionsAnimalsAntimalarialsAotidaeArtemisininsArtesunateDisease Models, AnimalMalaria, FalciparumParasitic Sensitivity TestsPhenotypePlasmodium falciparumPrimatesQuantitative Trait LociTreatment FailureAntimalarialsArtemisininsArtesunate

Identifiers

PMID26880111
PMCPMC4754742
OpenAlexW2344659469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.